Skip to main content
Top
Published in: Familial Cancer 1/2018

01-01-2018 | Original Article

Quality of life following prophylactic gynecological surgery: experiences of female Lynch mutation carriers

Authors: Holly Etchegary, Elizabeth Dicks, Laura Tamutis, Lesa Dawson

Published in: Familial Cancer | Issue 1/2018

Login to get access

Abstract

Lynch syndrome (LS) is a genetic condition conferring an elevated risk of gastrointestinal, gynecologic and other malignancies, often before the age of 50. Current guidelines recommend prophylactic gynecologic surgery to manage inherited cancers for female mutation carriers. Data is lacking on women’s quality of life following surgery. In this pilot study, we explored how women described their quality of life post-prophylactic gynecologic surgery and the factors that affected post-surgery experiences. A qualitative interview study was the chosen design. Ten female Lynch syndrome mutation carriers were interviewed by phone. Interviews were transcribed and analysed for themes relating to quality of life post-surgery using content analysis and constant comparison. Women largely reported doing well since their surgeries, though all described deleterious impacts on quality of life. Positive impacts of surgery included a reduction in cancer worry and an increase in healthy lifestyle behaviors, while negative impacts due to the sudden onset of menopause and impact on sexual function were common. Pre-surgical knowledge, drug and topical therapies, and post-surgical support all contributed to a positive quality of life. This small pilot study revealed increased endocrine symptoms and a negative impact on sexual health following prophylactic gynecological surgery. Women who were informed of potential symptoms pre-surgery coped better with surgical outcomes, as did women using some form of HRT. All women experienced reduced cancer worry post-surgery. Findings highlight areas for discussion in pre-operative settings (e.g., sexual health), as well as the need for better follow-up support post-surgery.
Appendix
Available only for authorised users
Literature
1.
go back to reference Stoffel E, Mukherjee B, Raymond V, Tayob N, Kastrinos F, Sparr J, Wang F, Bandipalliam P, Syngal S, Gruber SB (2009) Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137:1621–1627CrossRefPubMedPubMedCentral Stoffel E, Mukherjee B, Raymond V, Tayob N, Kastrinos F, Sparr J, Wang F, Bandipalliam P, Syngal S, Gruber SB (2009) Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137:1621–1627CrossRefPubMedPubMedCentral
2.
go back to reference Aarnio M, Mecklin J, Aaltonen L, Nystrom-Lahti M, Jarvinen H (1995) Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNCC) syndrome. Int J Cancer 64:430–433CrossRefPubMed Aarnio M, Mecklin J, Aaltonen L, Nystrom-Lahti M, Jarvinen H (1995) Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNCC) syndrome. Int J Cancer 64:430–433CrossRefPubMed
3.
go back to reference Jarvinen H, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen L, Mecklin J (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793–4797CrossRefPubMed Jarvinen H, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen L, Mecklin J (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793–4797CrossRefPubMed
4.
go back to reference Lynch H, Casey M, Snyder C, Bewtra C, Lynch F, Butts M, Godwin A (2009) Hereditary ovarian cancer: molecular genetics, pathology, management and heterogeneity. Mol Oncol 3(2):97–147CrossRefPubMedPubMedCentral Lynch H, Casey M, Snyder C, Bewtra C, Lynch F, Butts M, Godwin A (2009) Hereditary ovarian cancer: molecular genetics, pathology, management and heterogeneity. Mol Oncol 3(2):97–147CrossRefPubMedPubMedCentral
5.
go back to reference Schmeler K, Daniels M, Soliman P, Broaddus R, Deavers M, Vu T, Chang G, Lu K (2010) Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol 115(2):434–434 Schmeler K, Daniels M, Soliman P, Broaddus R, Deavers M, Vu T, Chang G, Lu K (2010) Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol 115(2):434–434
6.
go back to reference Chapman J, Jacoby V, Chen L (2015) Managing symptoms and maximizing quality of life after preventive interventions for cancer risk reduction. Curr Opin Obstet Gynecol 27:40–44CrossRefPubMed Chapman J, Jacoby V, Chen L (2015) Managing symptoms and maximizing quality of life after preventive interventions for cancer risk reduction. Curr Opin Obstet Gynecol 27:40–44CrossRefPubMed
7.
go back to reference Lindor NM, Gloria MP, Donald WH, Anita YK, Miesfeldt S, Karen HL (2006) Recommendations for the care of individuals with an inherited predisposition to lynch syndrome: A systematic review. JAMA 296:1507–1517CrossRefPubMed Lindor NM, Gloria MP, Donald WH, Anita YK, Miesfeldt S, Karen HL (2006) Recommendations for the care of individuals with an inherited predisposition to lynch syndrome: A systematic review. JAMA 296:1507–1517CrossRefPubMed
8.
go back to reference McCann G, Eisenhauer E (2014) Hereditary cancer syndromes with high risk of endometrial and ovarian cancer: Surgical options for personalized care. J Surg Oncol. doi:10.1002/jso.23743 PubMed McCann G, Eisenhauer E (2014) Hereditary cancer syndromes with high risk of endometrial and ovarian cancer: Surgical options for personalized care. J Surg Oncol. doi:10.​1002/​jso.​23743 PubMed
9.
go back to reference Auranen A, Joutsiniemi T (2011) A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand 90:437–444CrossRefPubMed Auranen A, Joutsiniemi T (2011) A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand 90:437–444CrossRefPubMed
10.
go back to reference Stuckless S, Green J, Dawson L, Barrett B, Woods M, Dicks E, Parfrey P (2013) Impact of gynecological screening in LS carriers with an MSH2 mutation. Clin Genet 83:359–364CrossRefPubMed Stuckless S, Green J, Dawson L, Barrett B, Woods M, Dicks E, Parfrey P (2013) Impact of gynecological screening in LS carriers with an MSH2 mutation. Clin Genet 83:359–364CrossRefPubMed
11.
go back to reference Schmeler K, Lynch H, Chen L, Munsell M, Soliman P, Clark M, White K Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261–269CrossRefPubMed Schmeler K, Lynch H, Chen L, Munsell M, Soliman P, Clark M, White K Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261–269CrossRefPubMed
12.
go back to reference Vasen H, Blanco I, Aktan-Collin K, Gopie J, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Møller P, Myrhoj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJ, Rahner N, Wijnen JT, Järvinen HJ, Möslein G, Mallorca Group (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations from a group of European experts. Gut 62:812–823.CrossRefPubMedPubMedCentral Vasen H, Blanco I, Aktan-Collin K, Gopie J, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Møller P, Myrhoj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJ, Rahner N, Wijnen JT, Järvinen HJ, Möslein G, Mallorca Group (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations from a group of European experts. Gut 62:812–823.CrossRefPubMedPubMedCentral
13.
go back to reference Parker W, Feskanich D, Broder M, Chang E, Shoupe D, Farquhar C, Berek JS, Manson JE (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 121(4):709–716CrossRefPubMedPubMedCentral Parker W, Feskanich D, Broder M, Chang E, Shoupe D, Farquhar C, Berek JS, Manson JE (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 121(4):709–716CrossRefPubMedPubMedCentral
14.
go back to reference Chapman J, Powell C, McLennan J, Crawford B, Mak J, Stewart N, Chen LM (2011) Surveillance of survivors: follow-up after risk reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers. Gynecol Oncol 122:339–343CrossRefPubMed Chapman J, Powell C, McLennan J, Crawford B, Mak J, Stewart N, Chen LM (2011) Surveillance of survivors: follow-up after risk reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers. Gynecol Oncol 122:339–343CrossRefPubMed
15.
go back to reference Bonadies D, Moyer A, Matloff E (2011) What I wish I’d known before surgery: BRCA carriers’ perspectives after bilateral salpingo-oophorectomy. Fam Cancer 10:79–85CrossRef Bonadies D, Moyer A, Matloff E (2011) What I wish I’d known before surgery: BRCA carriers’ perspectives after bilateral salpingo-oophorectomy. Fam Cancer 10:79–85CrossRef
16.
go back to reference Fang C, Cherry C, Devarajan K, Li T, Malick J, Daly MB (2009) A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol Oncol 112:594–600CrossRefPubMedPubMedCentral Fang C, Cherry C, Devarajan K, Li T, Malick J, Daly MB (2009) A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol Oncol 112:594–600CrossRefPubMedPubMedCentral
17.
go back to reference Shuster L, Gostout B, Grossardt B, Rocca W (2008) Prophylactic oophorectomy in pre-menopausal women and long-term health—a review. Menopause Int 14:111–116PubMedPubMedCentral Shuster L, Gostout B, Grossardt B, Rocca W (2008) Prophylactic oophorectomy in pre-menopausal women and long-term health—a review. Menopause Int 14:111–116PubMedPubMedCentral
18.
go back to reference Johansen N, Liavaag A, Tanbo T, Dahl A, Pripp A, Michelsen T (2016) Sexual activity and functioning after risk-reducing salpingo-oophorectomy: impact of hormone replacement therapy. Gynecol Oncol 140:101–106CrossRefPubMed Johansen N, Liavaag A, Tanbo T, Dahl A, Pripp A, Michelsen T (2016) Sexual activity and functioning after risk-reducing salpingo-oophorectomy: impact of hormone replacement therapy. Gynecol Oncol 140:101–106CrossRefPubMed
19.
go back to reference Finch A, Metcalfe K, Chiang J, Elit L, McLaughlin J, Springate C, Demsky R, Murphy J, Rosen B, Narod SA (2011) The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 121:163–168CrossRefPubMed Finch A, Metcalfe K, Chiang J, Elit L, McLaughlin J, Springate C, Demsky R, Murphy J, Rosen B, Narod SA (2011) The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 121:163–168CrossRefPubMed
20.
go back to reference Tucker P, Bulsara M, Salfinger S, Tan J, Green H, Cohen P (2016) Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy. Gynecol Oncol 140:95–100CrossRefPubMed Tucker P, Bulsara M, Salfinger S, Tan J, Green H, Cohen P (2016) Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy. Gynecol Oncol 140:95–100CrossRefPubMed
21.
go back to reference Madalinska J, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir H, Massuger L, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK (2005) Quality of life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23:6890–6898CrossRefPubMed Madalinska J, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir H, Massuger L, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK (2005) Quality of life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23:6890–6898CrossRefPubMed
22.
go back to reference Moldovan R, Keating S, Clancy T (2015) The impact of risk-reducing gynaecological surgery in premenopausal women at high risk of endometrial and ovarian cancer due to Lynch syndrome. Fam Cancer 14:51–60CrossRefPubMed Moldovan R, Keating S, Clancy T (2015) The impact of risk-reducing gynaecological surgery in premenopausal women at high risk of endometrial and ovarian cancer due to Lynch syndrome. Fam Cancer 14:51–60CrossRefPubMed
23.
go back to reference Miller S, Roussi P, Mary B, Scarpato J (2010) New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin Cancer Res 16:5094–5106CrossRefPubMedPubMedCentral Miller S, Roussi P, Mary B, Scarpato J (2010) New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin Cancer Res 16:5094–5106CrossRefPubMedPubMedCentral
24.
go back to reference Brotto L, Branco N, Dunkley C, McCullum M, McApline J (2012) Risk-reducing bilateral salpingo-oophorectomy and sexual health: a qualitative study. J Obstet Gynaecol Can 34:172–178CrossRefPubMed Brotto L, Branco N, Dunkley C, McCullum M, McApline J (2012) Risk-reducing bilateral salpingo-oophorectomy and sexual health: a qualitative study. J Obstet Gynaecol Can 34:172–178CrossRefPubMed
25.
go back to reference Etchegary H, Dicks E, Watkins K, Alani S, Dawson L (2015) Decisions about prophylactic gynecologic surgery: a qualitative study of the experience of female Lynch syndrome mutation carriers. Hered Cancer Clin Pract 13(1):10CrossRefPubMedPubMedCentral Etchegary H, Dicks E, Watkins K, Alani S, Dawson L (2015) Decisions about prophylactic gynecologic surgery: a qualitative study of the experience of female Lynch syndrome mutation carriers. Hered Cancer Clin Pract 13(1):10CrossRefPubMedPubMedCentral
26.
go back to reference Yurgelun M, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad, Blanco A, Shannon KM, Chung DC, Terdiman J, Gruber SB, Garber JE, Syngal S, Stoffel EM (2012) Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol 127:544–551CrossRefPubMedPubMedCentral Yurgelun M, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad, Blanco A, Shannon KM, Chung DC, Terdiman J, Gruber SB, Garber JE, Syngal S, Stoffel EM (2012) Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol 127:544–551CrossRefPubMedPubMedCentral
27.
29.
go back to reference Glaser B, Strauss A (1967) The discovery of grounded theory. Aldine, Chicago Glaser B, Strauss A (1967) The discovery of grounded theory. Aldine, Chicago
30.
go back to reference Marchetti C, Iadarola R, Palaia I, di Donato V, Perniola G, Muzii L, Panici PB (2014) Hormone therapy in oophorectomized BRCA 1/2 mutation carriers. Menopause 21:763–768CrossRefPubMed Marchetti C, Iadarola R, Palaia I, di Donato V, Perniola G, Muzii L, Panici PB (2014) Hormone therapy in oophorectomized BRCA 1/2 mutation carriers. Menopause 21:763–768CrossRefPubMed
31.
go back to reference Brain K, Gravell C, France E, Fiander A, Gray J (2004) An exploratory qualitative study of women’s perceptions of risk management options for familial ovarian cancer: implications for informed decision making. Gynecol Oncol 92:905–913CrossRefPubMed Brain K, Gravell C, France E, Fiander A, Gray J (2004) An exploratory qualitative study of women’s perceptions of risk management options for familial ovarian cancer: implications for informed decision making. Gynecol Oncol 92:905–913CrossRefPubMed
32.
go back to reference Tiller K, Meiser B, Gould L, Tucker K, Dudding T, Franklin J, Friedlander M, Andrews L (2005) Knowledge of risk management strategies and information and risk management preferences of women at increased risk for ovarian cancer. Psychooncology 14:249–261CrossRefPubMed Tiller K, Meiser B, Gould L, Tucker K, Dudding T, Franklin J, Friedlander M, Andrews L (2005) Knowledge of risk management strategies and information and risk management preferences of women at increased risk for ovarian cancer. Psychooncology 14:249–261CrossRefPubMed
33.
go back to reference Watkins K, Way, C, Fiander J, Meadus R, Esplen MJ, Green J, Ludlow VC, Etchegary H, Parfrey P (2011) Lynch syndrome: barriers and facilitators of screening and disease management. Hered Cancer Clin Pract 9:8CrossRefPubMedPubMedCentral Watkins K, Way, C, Fiander J, Meadus R, Esplen MJ, Green J, Ludlow VC, Etchegary H, Parfrey P (2011) Lynch syndrome: barriers and facilitators of screening and disease management. Hered Cancer Clin Pract 9:8CrossRefPubMedPubMedCentral
34.
go back to reference Barrow P, Khan M, Lalloo F, Evans D, Hill J (2013) Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br J Surg 100(Suppl 7):123–124 Barrow P, Khan M, Lalloo F, Evans D, Hill J (2013) Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br J Surg 100(Suppl 7):123–124
Metadata
Title
Quality of life following prophylactic gynecological surgery: experiences of female Lynch mutation carriers
Authors
Holly Etchegary
Elizabeth Dicks
Laura Tamutis
Lesa Dawson
Publication date
01-01-2018
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-9997-6

Other articles of this Issue 1/2018

Familial Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine